Novartis Expiry of Patent for Blockbuster Vildagliptin to Clear Way for Competitors Farhat Nasim30 July 2019 2:08 PM ISTNew Delhi: The patent protection of blockbuster anti-diabetic drug Vildagliptin manufactured by the Swiss drugmaker, Novartis, will soon expire on...
Novartis, Abbott, Emcure face allegations of cartelisation in anti-diabetes drug Vildagliptin savita thakur thakur26 March 2017 11:33 AM ISTThe Swiss drug maker Novartis and US based Abbott along with domestic companies Emcure and USV Pharma are under the lens of Health Ministry and...